In this secondary analysis of the MINT trial, 30-day risks for the composite outcome of death and recurrent myocardial ...

In this randomized controlled trial, patients with metabolic syndrome who underwent time-restricted eating in addition to ...

In this randomized controlled trial, in patients diagnosed with migraine, it was found that administration of a monoclonal ...

The 5-year OS rate for pembrolizumab vs placebo was 86.1% vs 81.7% with HR 0.51 (significant). 2. Immune-mediated adverse ...

Epkinly showed an overall response rate of 82% with 62.5% of patients achieving complete response. 65% of patients had grade 1-2 cytokine release syndrome (CRS), though severe cases (grade 3) were ...